Hye-Jeong Jo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hye-Jeong Jo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chanmi Park
HCI Lab, Yonsei University, Seoul, Republic of Korea
2 shared publications - Eunji Kim
Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
2 shared publications - Hanna Kim
HAII Corp, Seoul, Republic of Korea
2 shared publications - Hyunsil Song
HCI Lab, Yonsei University, Seoul, Republic of Korea
2 shared publications - Jae-Jin Kim
Institute of Behavioral Sciences in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Psychiatry, Yonsei University College of Medicine, Seoul, Republic of Korea
2 shared publications - Jee Hang Lee
Department of Human-Centered AI, Sangmyung University, Seoul 03016, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 12 December 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e69981
Anzeilax, a Smartphone-based Digital Therapeutic for Generalized Anxiety Disorder: A Randomized Controlled Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Individuals with generalized anxiety disorder (GAD) often face challenges with self-regulation and limited access to traditional therapy. While Acceptance and Commitment Therapy (ACT) has demonstrated both efficacy and effectiveness in promoting psychological flexibility, scalable solutions are necessary to address these barriers. This study introduces Anzeilax, an ACT-based digital therapeutic (DTx) that incorporates self-talk as a novel mechanism of action (MoA) to enhance psychological flexibility in the treatment of GAD. Objective: This study aimed to evaluate the efficacy of Anzeilax in reducing anxiety symptoms in individuals with GAD. Methods: A 10-week, parallel-group, superiority randomized controlled trial was conducted with 96 participants diagnosed with GAD (GAD-7 scores ≥10, age ≥19 years). The participants were randomly assigned (1:1) to receive either Anzeilax, a self-guided ACT-based DTx incorporating self-talk content alongside treatment-as-usual (n=48), or treatment-as-usual alone (n=48). Only the outcome evaluators were blinded to the group assignment. The primary outcome was the change in GAD-7 score from baseline to week 10. The secondary outcomes included the Beck Anxiety Inventory (BAI) for anxiety symptoms, the Penn State Worrying Questionnaire (PSWQ) for pathological worry, and the Hospital Anxiety and Depression Scale (HADS) for anxiety and depression symptoms. All self-report outcomes were assessed at baseline and at weeks 5, 10 (post-intervention), and 15 (follow-up). Results: During the trial, 34 (71%) and 31 (65%) participants in the treatment group maintained at least 80% of the prescribed usage frequency at weeks 5 and 10, respectively. Based on the Full Analysis Set (FAS), participants using Anzeilax demonstrated significant improvement in anxiety symptoms compared to the control group. Analysis of the primary outcome at 10 weeks post-intervention compared to baseline exhibited a significant reduction in GAD-7 scores (adjusted mean difference: -2.26; 95% CI: -3.78 to -0.74, P=.002). Secondary outcomes at the same time point indicated consistent improvements, with significant group-by-time interactions observed in the GAD-7 (P=.008, Cohen d=0.60), BAI (P=.008, Cohen d=0.50), PSWQ (P=.002, Cohen d=0.62), and HADS-A (P=.014, Cohen d=0.50). These improvements were sustained throughout the 15-week follow-up period. While the differences in depressive symptoms between the two groups did not present statistical significance, notable improvements were observed in the treatment group. Conclusions: Anzeilax demonstrated clinically meaningful efficacy in reducing anxiety symptoms when combined with treatment-as-usual. The results showed consistent improvements across multiple anxiety measures, with effects sustained through follow-up. The incorporation of context-sensitive self-talk within an ACT-based DTx framework offers a promising and accessible solution for treating individuals with GAD. Clinical Trial: ClinicalTrials.gov NCT06010654
- 12 December 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e69981
Open AccessAnzeilax, a Smartphone-based Digital Therapeutic for Generalized Anxiety Disorder: A Randomized Controlled Trial (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Individuals with generalized anxiety disorder (GAD) often face challenges with self-regulation and limited access to traditional therapy. While Acceptance and Commitment Therapy (ACT) has demonstrated both efficacy and effectiveness in promoting psychological flexibility, scalable solutions are necessary to address these barriers. This study introduces Anzeilax, an ACT-based digital therapeutic (DTx) that incorporates self-talk as a novel mechanism of action (MoA) to enhance psychological flexibility in the treatment of GAD. Objective: This study aimed to evaluate the efficacy of Anzeilax in reducing anxiety symptoms in individuals with GAD. Methods: A 10-week, parallel-group, superiority randomized controlled trial was conducted with 96 participants diagnosed with GAD (GAD-7 scores ≥10, age ≥19 years). The participants were randomly assigned (1:1) to receive either Anzeilax, a self-guided ACT-based DTx incorporating self-talk content alongside treatment-as-usual (n=48), or treatment-as-usual alone (n=48). Only the outcome evaluators were blinded to the group assignment. The primary outcome was the change in GAD-7 score from baseline to week 10. The secondary outcomes included the Beck Anxiety Inventory (BAI) for anxiety symptoms, the Penn State Worrying Questionnaire (PSWQ) for pathological worry, and the Hospital Anxiety and Depression Scale (HADS) for anxiety and depression symptoms. All self-report outcomes were assessed at baseline and at weeks 5, 10 (post-intervention), and 15 (follow-up). Results: During the trial, 34 (71%) and 31 (65%) participants in the treatment group maintained at least 80% of the prescribed usage frequency at weeks 5 and 10, respectively. Based on the Full Analysis Set (FAS), participants using Anzeilax demonstrated significant improvement in anxiety symptoms compared to the control group. Analysis of the primary outcome at 10 weeks post-intervention compared to baseline exhibited a significant reduction in GAD-7 scores (adjusted mean difference: -2.26; 95% CI: -3.78 to -0.74, P=.002). Secondary outcomes at the same time point indicated consistent improvements, with significant group-by-time interactions observed in the GAD-7 (P=.008, Cohen d=0.60), BAI (P=.008, Cohen d=0.50), PSWQ (P=.002, Cohen d=0.62), and HADS-A (P=.014, Cohen d=0.50). These improvements were sustained throughout the 15-week follow-up period. While the differences in depressive symptoms between the two groups did not present statistical significance, notable improvements were observed in the treatment group. Conclusions: Anzeilax demonstrated clinically meaningful efficacy in reducing anxiety symptoms when combined with treatment-as-usual. The results showed consistent improvements across multiple anxiety measures, with effects sustained through follow-up. The incorporation of context-sensitive self-talk within an ACT-based DTx framework offers a promising and accessible solution for treating individuals with GAD. Clinical Trial: ClinicalTrials.gov NCT06010654
- Open Access
- 12 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Anzeilax, a Smartphone-based Digital Therapeutic for Generalized Anxiety Disorder: A Randomized Controlled Trial (Preprint)
BACKGROUND Individuals with generalized anxiety disorder (GAD) often face challenges with self-regulation and limited access to traditional therapy. While Acceptance and Commitment Therapy (ACT) has demonstrated both efficacy and effectiveness in promoting psychological flexibility, scalable solutions are necessary to address these barriers. This study introduces Anzeilax, an ACT-based digital therapeutic (DTx) that incorporates self-talk as a novel mechanism of action (MoA) to enhance psychological flexibility in the treatment of GAD. OBJECTIVE This study aimed to evaluate the efficacy of Anzeilax in reducing anxiety symptoms in individuals with GAD. METHODS A 10-week, parallel-group, superiority randomized controlled trial was conducted with 96 participants diagnosed with GAD (GAD-7 scores ≥10, age ≥19 years). The participants were randomly assigned (1:1) to receive either Anzeilax, a self-guided ACT-based DTx incorporating self-talk content alongside treatment-as-usual (n=48), or treatment-as-usual alone (n=48). Only the outcome evaluators were blinded to the group assignment. The primary outcome was the change in GAD-7 score from baseline to week 10. The secondary outcomes included the Beck Anxiety Inventory (BAI) for anxiety symptoms, the Penn State Worrying Questionnaire (PSWQ) for pathological worry, and the Hospital Anxiety and Depression Scale (HADS) for anxiety and depression symptoms. All self-report outcomes were assessed at baseline and at weeks 5, 10 (post-intervention), and 15 (follow-up). RESULTS During the trial, 34 (71%) and 31 (65%) participants in the treatment group maintained at least 80% of the prescribed usage frequency at weeks 5 and 10, respectively. Based on the Full Analysis Set (FAS), participants using Anzeilax demonstrated significant improvement in anxiety symptoms compared to the control group. Analysis of the primary outcome at 10 weeks post-intervention compared to baseline exhibited a significant reduction in GAD-7 scores (adjusted mean difference: -2.26; 95% CI: -3.78 to -0.74, P=.002). Secondary outcomes at the same time point indicated consistent improvements, with significant group-by-time interactions observed in the GAD-7 (P=.008, Cohen d=0.60), BAI (P=.008, Cohen d=0.50), PSWQ (P=.002, Cohen d=0.62), and HADS-A (P=.014, Cohen d=0.50). These improvements were sustained throughout the 15-week follow-up period. While the differences in depressive symptoms between the two groups did not present statistical significance, notable improvements were observed in the treatment group. CONCLUSIONS Anzeilax demonstrated clinically meaningful efficacy in reducing anxiety symptoms when combined with treatment-as-usual. The results showed consistent improvements across multiple anxiety measures, with effects sustained through follow-up. The incorporation of context-sensitive self-talk within an ACT-based DTx framework offers a promising and accessible solution for treating individuals with GAD. CLINICALTRIAL ClinicalTrials.gov NCT06010654
- 12 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAnzeilax, a Smartphone-based Digital Therapeutic for Generalized Anxiety Disorder: A Randomized Controlled Trial (Preprint)
BACKGROUND Individuals with generalized anxiety disorder (GAD) often face challenges with self-regulation and limited access to traditional therapy. While Acceptance and Commitment Therapy (ACT) has demonstrated both efficacy and effectiveness in promoting psychological flexibility, scalable solutions are necessary to address these barriers. This study introduces Anzeilax, an ACT-based digital therapeutic (DTx) that incorporates self-talk as a novel mechanism of action (MoA) to enhance psychological flexibility in the treatment of GAD. OBJECTIVE This study aimed to evaluate the efficacy of Anzeilax in reducing anxiety symptoms in individuals with GAD. METHODS A 10-week, parallel-group, superiority randomized controlled trial was conducted with 96 participants diagnosed with GAD (GAD-7 scores ≥10, age ≥19 years). The participants were randomly assigned (1:1) to receive either Anzeilax, a self-guided ACT-based DTx incorporating self-talk content alongside treatment-as-usual (n=48), or treatment-as-usual alone (n=48). Only the outcome evaluators were blinded to the group assignment. The primary outcome was the change in GAD-7 score from baseline to week 10. The secondary outcomes included the Beck Anxiety Inventory (BAI) for anxiety symptoms, the Penn State Worrying Questionnaire (PSWQ) for pathological worry, and the Hospital Anxiety and Depression Scale (HADS) for anxiety and depression symptoms. All self-report outcomes were assessed at baseline and at weeks 5, 10 (post-intervention), and 15 (follow-up). RESULTS During the trial, 34 (71%) and 31 (65%) participants in the treatment group maintained at least 80% of the prescribed usage frequency at weeks 5 and 10, respectively. Based on the Full Analysis Set (FAS), participants using Anzeilax demonstrated significant improvement in anxiety symptoms compared to the control group. Analysis of the primary outcome at 10 weeks post-intervention compared to baseline exhibited a significant reduction in GAD-7 scores (adjusted mean difference: -2.26; 95% CI: -3.78 to -0.74, P=.002). Secondary outcomes at the same time point indicated consistent improvements, with significant group-by-time interactions observed in the GAD-7 (P=.008, Cohen d=0.60), BAI (P=.008, Cohen d=0.50), PSWQ (P=.002, Cohen d=0.62), and HADS-A (P=.014, Cohen d=0.50). These improvements were sustained throughout the 15-week follow-up period. While the differences in depressive symptoms between the two groups did not present statistical significance, notable improvements were observed in the treatment group. CONCLUSIONS Anzeilax demonstrated clinically meaningful efficacy in reducing anxiety symptoms when combined with treatment-as-usual. The results showed consistent improvements across multiple anxiety measures, with effects sustained through follow-up. The incorporation of context-sensitive self-talk within an ACT-based DTx framework offers a promising and accessible solution for treating individuals with GAD. CLINICALTRIAL ClinicalTrials.gov NCT06010654